anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Inflammation in the bone marrow (BM) microenvironment is a constitutive component of leukemogenesis in acute myeloid leukemia (AML). Current evidence suggests that both leukemic blasts and stroma secrete proinflammatory factors that actively suppress the function of healthy hematopoietic stem and progenitor cells (HSPCs). HSPCs are also cellular components of the innate immune system, and we reasoned that they may actively propagate the inflammation in the leukemic niche. In two separate congenic models of AML we confirm by evaluation of the BM plasma secretome and HSPC-selective single-cell RNA sequencing (scRNA-Seq) that multipotent progenitors and long-lived stem cells adopt inflammatory gene expression programs, even at low leukemic infiltration of the BM. In particular, we observe interferon gamma (IFN-γ) pathway activation, along with secretion of its chemokine target, CXCL10. We show that AML-derived nanometer-sized extracellular vesicles (EVAML) are sufficient to trigger this inflammatory HSPC response, both in vitro and in vivo. Altogether, our studies indicate that HSPCs are an unrecognized component of the inflammatory adaptation of the BM by leukemic cells. The pro-inflammatory conversion and long-lived presence of HSPCs in the BM along with their regenerative re-expansion during remission may impact clonal selection and disease evolution.
PURPOSE: To obtain an antimicrobial preparation exhibiting excellent antimicrobial activity against the aggregate and lump of microorganisms, such as a biofilm or plaque, which can substantially not be controlled with an antimicrobial agent alone. CONSTITUTION: The antimicrobial preparation contains 0.001-10wt.% of lysine or its derivative, 0.001-10wt.% of a compound exhibiting antimicrobial activity, and 0.005-5wt.% of at least a surfactant selected from a nonionic surfactant and an amphoteric surfactant. The compound exhibiting the antimicrobial activity includes cationic antimicrobial agents (e.g. benzalkonium chloride), fluorides, natural antimicrobial agents (e.g. oil-soluble glycyrrhiza extract, propolis, aloe extract), trichlosan, and isopropylmethylphenol. The nonionic surfactant is preferably a polyethylene oxide-polypropylene oxide block copolymer, and the amphoteric surfactant is preferably a 2-alkyl-N-carboxymethyl-N- hydroxyethylimidazolinium betaine.
INTRODUCTION: Recent data suggests that infrarenal abdominal aortic aneurysm (AAA) endovascular repair (EVAR) with large diameter grafts (LGs) may have a higher risk of endoleak and reintervention. However, this has not been studied extensively for fenestrated endovascular aneurysm repair (fEVAR). We, therefore, sought to evaluate the outcomes of patients undergoing fEVAR with large-diameter endografts.
METHODS: Patients from the national Vascular Quality Initiative registry who underwent fEVAR for intact juxtarenal AAA were identified. Patients with genetic causes for aneurysms, those with prior aortic surgery, and those undergoing repair for symptomatic or ruptured aneurysms were excluded. Rates of endoleaks and reintervention at periprocedural and long-term follow-up timepoints (9-22 mo) were analyzed in grafts 32 mm or larger (LG) and were compared to those smaller than 32 mm (small diameter graft).
RESULTS: A total of 693 patients (22.8% LG) were identified. Overall, demographic variables were comparable except LG exhibited a more frequent history of coronary artery disease (32.9% versus 25.4%, P = 0.037). There were no significant differences in the rates of endoleak at procedural completion. Overall survival at 5 y was no different. The rate of reintervention at 1 y was also no different (log-rank P = 0.86).
CONCLUSIONS: While graft size appears to have an association with outcomes in infrarenal aneurysm repair, the same does not appear to be true for fEVAR. Further studies should evaluate the long-term outcomes associated with LG which could alter the approach to repair of AAA with large neck diameters traditionally treated with standard infrarenal EVAR.
The present invention is directed towards novel cyclic phosph(oramid)ate prodrugs of alcohol, amine-, and thiol-containing drugs, their preparation, their synthetic intermediates, and their uses. Another aspect of the invention is the use of the prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells that express cytochrome P450, including hepatitis, cancer, liver fibrosis, malaria, other viral and parasitic infections, and metabolic diseases where the liver responsible for the overproduction of the biochemical end product, e.g. glucose (diabetes); cholesterol, fatty acids and triglycerides (hyperlipidemia) (atherosclerosis) (obesity). In one apsect, the invention is directed towards the use of the prodrugs to enhance oral drug delivery. In another aspect, the prodrugs are used to prolong pharmacodynamic half-life of the drug. In addition, the prodrug methodology of the current invention is used to achieve sustained delivery of the parent drug. In another aspect, the prodrugs are used to increase the therapeutic index of the drug. In another aspect of the invention, a method of making these prodrugs is described. In another aspect, the prodrugs are also useful in the delivery of diagnostic imaging agents to the liver.
The present invention relates to a-linolenic acid enriched polyene phosphatidylcholine and a production method thereof. 20 to 40 wt. % of the a-linolenic acid is contained in fatty acid composition, the acid value is 5-40 mgKOH/g, the iodine value is 80-130gI2 /100g, and the phosphorus content is from 2.7 to 3.8%. In the production method, high-purity egg lecithin is used as a raw material, and is mixed with a-linolenic acid enriched grease, and the a-linolenic acid enriched polyene phosphatidylcholine is generated through biologic enzyme catalysis ester exchange. The present invention has the advantages of easy ester interchange reaction, exertion of the double action of polyunsaturated fatty acid and phospholipid, solventliss reaction system, stable phospholipid type a-linolenic acid, etc. The polyunsaturated fatty acid is the a-linolenic acid, and separtion problem is solved through the super critical extraction and separation of reaction products.
One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
A considerable number of patients suffer acute coronary events despite being treated with antiplatelet therapy such as aspirin. Taken together with laboratory findings of a low response to aspirin, the term "aspirin resistance" has been coined. Diabetics have an increased risk of suffering ischemic vascular events and, recently, an increased prevalence of "aspirin resistance" was reported in these patients. The purpose of the present study is to compare the aspirin response in diabetics and non-diabetics in a population with angiogram-verified coronary artery disease. Furthermore, healthy volunteers and patients who suffered a myocardial infarction while being treated with aspirin are included. Eligible patients are identified in the Western Denmark Heart Registry.
To provide an inorganic particle with a hydrophobic surface, which expresses excellent slipperiness, soft focus property, and/or fine wrinkles hiding effect when applied to the skin, and has useful properties as cosmetic raw material, and a method for producing the same.SOLUTION: The present disclosure provides a hydrophobic plate-like inorganic particle in which the surface of a plate-like inorganic particle is coated with a cured product of a room-temperature-curable silicone composition, where, the room-temperature-curable silicone composition contains: a first oligomer that contains a dialkylsiloxane unit and an alkoxy group-containing siloxane unit; a second oligomer that does not contain a dialkylsiloxane unit and contains an alkoxy group-containing siloxane unit; silicone oil; a catalyst; and an organic solvent. In the room-temperature-curable silicone composition, the total content ratio of the first oligomer and the second oligomer is 20 mass% or more and 50 mass% or less. The content ratio of the first oligomer relative to 1 pt.mass of the second oligomer is 0.15 pt.mass or more and 10 pts.mass or less. The silicone oil has a kinematic viscosity at 25°C of 100 mm2/s or more. The catalyst is at least one selected from the group consisting of metalalkoxide, a metal chelate compound and metal carboxylate. The organic solvent has a vapor pressure at 20°C of l kPa or more.SELECTED DRAWING: None
Racial disparities in pediatric kidney transplantation have been well described over the last two decades and include disparities in preemptive transplantation, waitlisting, time from activation to transplantation, living donation, and graft outcomes. Changes to the organ allocation system including the institution of Share 35 in 2005 and the Kidney Allocation System (KAS) of 2014 have resulted in resolution of some, but not all racial-ethnic disparities. Despite overall improvements in time from waitlist activation to transplant, disparities remain in preemptive transplantation, time to waitlisting, and living donor transplantation. Although improving under the KAS, racial disparities remain in graft survival as well. Racial disparity in kidney transplant access and graft survival is an international problem within pediatric nephrology. Although the racial group affected may differ, various minoritized pediatric groups across the world are affected by transplant disparities. Social determinants of health including financial access, language barriers, and the presence of a healthy living donor play a role in mediating these disparities. Further investigation is needed to better understand and intervene upon modifiable social, biological, and cultural factors driving the remaining disparity in transplant outcomes.
PURPOSE:The titled inducer having low toxicity containing polysilsesquioxane as an active ingradient. CONSTITUTION:An interferon inducer containing a polysilsesquioxane consisting of a constitutional unit shown by the formula I (X is Br, alkyl, cyano, or phenoxy) as an active ingredient. It has improved characteristics of producing interferon a relatively long time after its administration. A dose is 800-1mg/kg/day, preferably 500-10mg/kg/day, once daily or several times, it is administered orally, parenterally, or to the affected part. The compound shown by the formula I is obtained easily by hydrolyzing a compound shown by the formula II (Y is halogen, or alkoxy) in a hydrous solvent. It is prepared as amorphous white or light yellow solid high polymer, a tridimensional cage or ladder polymer.
The purpose of the present invention is to provide particles having excellent slipperiness and a soft texture, and uses thereof.　(Particles of first embodiment) Particles having an average particle diameter of 0.5-100 μm, a compressive aggregate modulus of 0-25% and a compressive recovery modulus of 60-100%. Preferably, the particles have a sphericity of 0.6-1.0. Preferably, the particles contain an organic polymer. Preferably, the organic polymer contains a thermoplastic resin. (Particles of second embodiment) Particles containing a thermoplastic resin and having an average particle diameter of 0.5-100 μm and a compressive aggregate modulus of 0-25%.
INTRODUCTION: Primary health care has regained its importance in global policy making. In 2018, the Government of India initiated the Ayushman Bharat - Comprehensive Primary Health Care (AB-CPHC) programme. It was based on upgrading the existing primary health facilities into Health and Wellness Centers (HWCs). The current study aimed to assess the readiness and performance of HWCs in providing comprehensive primary health care services in India's Chhattisgarh state.
METHODS: We conducted a cross-sectional health facility assessment with a state-representative sample of 404 HWCs. A standardized health facility survey tool was used to collect information on essential inputs and service outputs of HWCs. The expected population healthcare needs were estimated using secondary sources. The performance of HWCs was assessed by comparing the volume of services provided against the expected population need for outpatient care.
RESULTS: On an average, 358 outpatients including 128 non-communicable disease (NCD) patients were treated monthly at an HWC. HWCs were able to cover 31% of the total population's health need for outpatient care, 26% for hypertension, and 21% for diabetes care. In addition to services for reproductive and child health, HWCs provided services for common acute ailments (cold, cough, fever, aches and pains); infections of skin, eye, ear, and reproductive tract, and minor injuries. HWCs were also contributing significantly to national disease control programmes. Acute ailments followed by NCDs and communicable diseases had the largest share among services provided. The key gaps were in coverage of mental illnesses and chronic respiratory diseases. Most of the HWCs showed adequate readiness for the availability of required human resources, supplies, and infrastructure.
CONCLUSION: HWCs were able to provide a comprehensive range of primary care services and able to cater to a sizable portion of the rural population's acute and chronic health care needs. The performance was made possible by the adequate availability of medicines, staff, training programmes and tele-consultation linkages. If HWCs in other states are able to reach a similar level of performance, the initiative will prove to be a game changer for equitable primary care in India.
Posterior inferior cerebellar artery aneurysms are likely to be fusiform, yet they hardly enlarge to mimic a tumor in the posterior fossa on radiology. They constitute about 3%-4% of all cerebral aneurysms. A 65-year-old woman presented with tremor in her right upper limb for 1 year and intermittent dizziness for 8 months. Interestingly, magnetic resonance imaging revealed 2 unanimously enhanced masses like mother and daughter located in the right cerebellum hemisphere. The lesion was resected via surgery, and histopathology established the diagnosis of an aneurysm. Her tremor and dizziness subsided 3 months after the surgery, and at her 2-year follow-up she was well with no further neurologic deficits.
The usual treatment of heroin addiction in Russia involves detoxification and 2-4 weeks of rehabilitation with referral to outpatient follow-up. Though most patients complete inpatient treatment, few keep follow-up appointments and relapse rates are high. More effective therapies are needed, especially in view of the epidemic of heroin addiction that has resulted in the spread of HIV and other infectious diseases. A recently-completed study of 52 patients randomized to oral naltrexone (ON) or oral naltrexone placebo (ONP) has shown efficacy in preventing relapse and reducing HIV risk but dropout was a problem with only 44% of ON patients proven to have not relapsed by 6 months (as compared to 16% of ONP patients). A larger study of 280 patients randomized to ON or ONP replicated these results and found some indication that adding an selective serotonin reuptake inhibitor (SSRI) to naltrexone may improve its efficacy in women, probably because they tend to have higher levels of psychiatric symptoms than men.

We think that retention and outcome can be improved by using a longer acting naltrexone preparation, and in this study we propose to compare ON with a depot naltrexone implant (DNI) that is manufactured and approved for use in Russia, and provides opioid blockade for 8-10 weeks. We will use a placebo-controlled, double-blind/double-dummy design since a placebo-controlled trial is required by the Russian equivalent of our FDA as a condition for testing a pharmacotherapy. Participants will be male and female heroin addicts who have been detoxified in addiction treatment hospitals or outpatient settings in St. Petersburg and have a family member willing and able to supervise medication adherence and facilitate follow-up. After giving informed consent and confirming the absence of physiologic dependence, 306 patients will be randomly assigned to a 6-month treatment in one of three groups of 102 each: oral naltrexone (ON) + depot naltrexone implant placebo (DNIP); oral naltrexone placebo (ONP) + depot naltrexone implant (DNI); or ONP + DNIP. All patients will receive biweekly clinical management/adherence enhancement counseling. Assessments will be done at baseline, at each biweekly appointment during the 6-months of medication treatment, and at 3 and 6 months following the end of study medication. Primary outcome will be the relapse free proportion at months 1-6; secondary outcomes will be time to dropout, opioid positive urines, HIV risk, use of alcohol and other drugs, psychiatric symptoms, and other measures of overall adjustment. We hypothesize that outcomes will be better with DNI than ON, and that each will be more effective than placebo.
BACKGROUND: The 2016 IDSA guideline recommends a treatment duration of at least 7 days for hospital-acquired (HAP)/ventilator-associated pneumonia (VAP). The limited literature has demonstrated higher rates of recurrence for non-glucose fermenting gram-negative bacilli with short course therapy, raising the concern of optimal treatment duration for these pathogens. Therefore, we aimed to compare the outcomes for patients receiving shorter therapy treatment (≤ 8 days) versus longer regimen (> 8 days) for the treatment of multidrug resistant (MDR) Pseudomonas pneumonia.
METHODS: A single-center, retrospective cohort study was conducted to evaluate adult patients receiving an antimicrobial regimen with activity against MDR Pseudomonas aeruginosa in respiratory culture between 2017 and 2020 for a minimum of 6 consecutive days. Exclusion criteria were inmates, those with polymicrobial pneumonia, community-acquired pneumonia, and infections requiring prolonged antibiotic therapy.
RESULTS: Of 427 patients with MDR P. aeruginosa respiratory isolates, 85 patients were included. Baseline characteristics were similar among groups with a median age of 65.5 years and median APACHE 2 score of 20. Roughly 75% had ventilator-associated pneumonia. Compared to those who received ≤ 8 days of therapy, no difference was seen for clinical success in patients treated for more than 8 days (80% vs. 65.5%, p = 0.16). The number of 30-day and 90-day in-hospital mortality, 30-days relapse, and other secondary outcomes did not significantly differ among the treatment groups.
CONCLUSIONS: Prolonging treatment duration beyond 8 days did not improve patient outcomes for MDR P. aeruginosa HAP/VAP.
PROBLEM TO BE SOLVED: To provide a wet tissue-type liniment capable of sanitarily and pleasantly treating without directly touching the affected part with a finger and moreover excellently applying a medicine to the affected part, an easy-to-use and sanitary packaged wet tissue-type liniment and a method for applying the same. SOLUTION: There are disclosed a wet tissue-type liniment comprising a base fabric retaining the medicine in the state of moisture retension and a packaged wet tissue-type liniment receiving the base fabric retaining the medicine in the state of moisture retension in a packaging bag. The medicine is preferably retained in the base fabric in the state of liquid. The medicine is an antipruritic and anti-inflammatory drug and preferably contains an antihistamic agent, a bactericide and a moistening agent. The liniment is suitably applied to a delicate part of the skin. A liniment receiving the base fabric retaining the medicine every piece of fabric in the packaging bag is preferable. The packaging bag is formed by a laminated film comprising polyethylene terephthalate layer/aluminium foil layer/unstretched polypropylene layer.  The method for applying the medicine by directly contacting the base fabric retaining the medicine to the part of body is disclosed.
Streptococcus suis is a pathogen causing serious disease in pigs. It may also be infectious to man. The Streptococcus suis adhesin protein is useful in diagnosis and therapy of said bacteria. Also fragmets of the unique N-terminal part of said protein are immunogenic and can be used in diagnosis an as vaccines. The invention therefore relates to said S. suis adhesin protein fragments, antibodies thereto and nucleotide sequences coding for said fragments. The invention further relates to immunoassay and PCR methods for diagnosing S. suis.
A vessel contains a liq. dental plaque-revealing agent (e. g. a soln. of >=1 suitable dye in a solvent such as water) and has an actuating means to propel the plaque-revealing agent from the vessel. The vessel can be an aerosol container from which the plaque-revealing agent is propelled under pressure from an aerosol propellant, but pref. the actuating means (e.g. a press-button) of the vessel operates a pump which dispenses the agent in a metered amt. (e.g. ca 0.5-1 ml). The vessel can be provided with a plastic or steel tube for insertion into the mouth to direct the jet of plaque-revealing agent onto the teeth.
INTRODUCTION: The aim of this study was to assess the feasibility of sparing routine antibiotic prophylaxis in patients without preoperative urinary tract infection undergoing ureterorenoscopy (URS) for stone removal.
METHODS: A retrospective, monocentric study was conducted to evaluate the outcome of a modified perioperative antibiotic management strategy according to the principles of antibiotic stewardship. Patients with preoperative unremarkable urine culture received no antibiotic prophylaxis for URS stone removal (NoPAP). The NoPAP group was compared to a historic URS cohort, when antibiotic prophylaxis (PAP) was standard of care. Analysis focused on postoperative complications.
RESULTS: Postoperative fever occurred in 1% of the NoPAP and 2% of the PAP patients (p = 0.589). Clavien 1-3 complications did not differ between groups with 9% in the NoPAP and 6.2% in the PAP (p = 0.159). No Clavien 4-5 complications were seen. We identified a residual stone (p = 0.033) and an ASA score 3-4 (p = 0.004) as significant risk factors for postoperative fever. By sparing routine antibiotic prophylaxis, the overall antibiotic usage was reduced from 100% (PAP) to 8.3% (NoPAP).
CONCLUSION: Sparing a routine antibiotic prophylaxis during URS for stone removal seems feasible in patients with unremarkable preoperative urine culture for most of the patients. A prospective validation is warranted.
The current literature addresses therapies for patients with resting PAH only, diagnosed by right heart catheterization. However, the World Health Organization (WHO) also recognizes and defines exercise induced pulmonary arterial hypertension (ex-PAH), which may precede the development of resting PAH. The natural progression of PAH, especially during exercise, has not been well delineated. An exercise hemodynamic study previously showed that in normal healthy subjects the mean pulmonary pressure does not exceed 30mmHg even at maximal cardiac outputs. A prior study evaluated exercise Doppler echocardiography systemic sclerosis patients with normal resting echocardiograms, finding an abnormal response which was defined as an estimated right ventricular systolic pressure greater than 40 mmHg. In the same study, 6.6% of the patients progressed to resting PAH over the followup period of 12 months. Limited data is available regarding the prevalence of ex-PAH in systemic sclerosis using right heart catheterization.